June Almenoff, MD, PhD
Independent
Tenure on this board
New nominee
7 nominees · 2 ballot items.
Elect seven director nominees to one-year terms and ratify Cherry Bekaert LLP as the independent registered public accounting firm for fiscal year 2026.
Elect the seven director nominees named in the proxy statement to serve one-year terms expiring in 2027 or until their successors are elected and qualified.
Ratify the appointment of Cherry Bekaert LLP as Tenax Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | PRICE T ROWE ASSOCIATES INC /MD/ | 11.1% | 2,951,116 | $47M |
| 2 | JANUS HENDERSON GROUP PLC | 6.8% | 1,815,474 | $29M |
| 3 | Venrock Adviser, LLC | 6.3% | 1,675,262 | $27M |
| 4 | PERCEPTIVE ADVISORS LLC | 5.5% | 1,447,782 | $23M |
| 5 | Ikarian Capital, LLC | 3.8% | 1,017,600 | $16M |
| 6 | Stonepine Capital Management, LLC | 3.7% | 975,200 | $16M |
| 7 | Logos Global Management LP | 2.4% | 625,000 | $10M |
| 8 | Velan Capital Investment Management LP | 2.2% | 583,333 | $9M |
| 9 | MORGAN STANLEY | 2.2% | 583,297 | $9M |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.0% | 540,126 | $9M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.